Insider Trading Alert - ASNA, SLH, ALXN, JAH And ITW Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Dec. 11, 2013, 145 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $117.00 to $353,142,000.00.

Highlighted Stocks Traded by Insiders:

Ascena Retail Group (ASNA) - FREE Research Report

Robinson Ronald who is Pres, Global Sourcing at Ascena Retail Group sold 2,145 shares at $20.38 on Dec. 11, 2013. Following this transaction, the Pres, Global Sourcing owned 21,441 shares meaning that the stake was reduced by 9.09% with the 2,145-share transaction.

Sullivan John J. who is EVP - Chief Operating Officer at Ascena Retail Group sold 2,640 shares at $20.43 on Dec. 11, 2013. Following this transaction, the EVP - Chief Operating Officer owned 13,508 shares meaning that the stake was reduced by 16.35% with the 2,640-share transaction.

The shares most recently traded at $20.10, down $0.33, or 1.63% since the insider transaction. Historical insider transactions for Ascena Retail Group go as follows:

  • 4-Week # shares sold: 17,148
  • 12-Week # shares sold: 193,413
  • 24-Week # shares sold: 193,413

The average volume for Ascena Retail Group has been 1.9 million shares per day over the past 30 days. Ascena Retail Group has a market cap of $3.3 billion and is part of the services sector and retail industry. Shares are up 9.47% year-to-date as of the close of trading on Wednesday.

Ascena Retail Group, Inc., through its subsidiaries, operates as a specialty retailer of apparel for women, and tween girls and boys. The company operates under the Justice, Lane Bryant, maurices, dressbarn, and Catherines segments. The company has a P/E ratio of 20.6. Currently there are 3 analysts that rate Ascena Retail Group a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ASNA - FREE

TheStreet Quant Ratings rates Ascena Retail Group as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in stock price during the past year, growth in earnings per share and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Ascena Retail Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Solera Holdings (SLH) - FREE Research Report

Aquila Tony who is President, CEO at Solera Holdings sold 6,500 shares at $69.85 on Dec. 11, 2013. Following this transaction, the President, CEO owned 310,436 shares meaning that the stake was reduced by 2.05% with the 6,500-share transaction.

The shares most recently traded at $67.84, down $2.01, or 2.96% since the insider transaction. Historical insider transactions for Solera Holdings go as follows:

  • 4-Week # shares sold: 10,541
  • 12-Week # shares sold: 15,773
  • 24-Week # shares sold: 15,773

The average volume for Solera Holdings has been 289,500 shares per day over the past 30 days. Solera Holdings has a market cap of $4.8 billion and is part of the technology sector and computer software & services industry. Shares are up 29.29% year-to-date as of the close of trading on Wednesday.

Solera Holdings, Inc. provides software and services to insurance companies, collision repair facilities, independent assessors, automotive recyclers, automotive dealers, and households in the United States and internationally. The stock currently has a dividend yield of 0.98%. The company has a P/E ratio of 64.6. Currently there are 6 analysts that rate Solera Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SLH - FREE

TheStreet Quant Ratings rates Solera Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Solera Holdings Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Alexion Pharmaceuticals (ALXN) - FREE Research Report

Parven Alvin S who is Director at Alexion Pharmaceuticals bought 140 shares at $84.95 on Dec. 11, 2013. Following this transaction, the Director owned 7,451 shares meaning that the stake was reduced by 1.91% with the 140-share transaction.

The shares most recently traded at $122.73, up $37.78, or 30.78% since the insider transaction. Historical insider transactions for Alexion Pharmaceuticals go as follows:

  • 12-Week # shares sold: 3,500
  • 24-Week # shares sold: 398,838

The average volume for Alexion Pharmaceuticals has been 1.0 million shares per day over the past 30 days. Alexion Pharmaceuticals has a market cap of $24.6 billion and is part of the health care sector and drugs industry. Shares are up 33.61% year-to-date as of the close of trading on Wednesday.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of life-transforming therapeutic products. The company has a P/E ratio of 70.8. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALXN - FREE

TheStreet Quant Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, growth in earnings per share and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Alexion Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Jarden Corporation (JAH) - FREE Research Report

Gaglione Patricia who is SVP, Bus. Ops. & Supply Chain at Jarden Corporation sold 24,586 shares at $57.27 on Dec. 11, 2013. Following this transaction, the SVP, Bus. Ops. & Supply Chain owned 48,837 shares meaning that the stake was reduced by 33.49% with the 24,586-share transaction.

The shares most recently traded at $57.19, down $0.08, or 0.14% since the insider transaction. Historical insider transactions for Jarden Corporation go as follows:

  • 4-Week # shares sold: 327,500
  • 12-Week # shares sold: 329,000
  • 24-Week # shares sold: 656,500

The average volume for Jarden Corporation has been 968,900 shares per day over the past 30 days. Jarden Corporation has a market cap of $7.5 billion and is part of the consumer goods sector and consumer durables industry. Shares are up 68.39% year-to-date as of the close of trading on Wednesday.

Jarden Corporation manufactures, markets, and distributes consumer products in the Unites States and internationally. The stock currently has a dividend yield of 1.01%. The company has a P/E ratio of 29.8. Currently there are 7 analysts that rate Jarden Corporation a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAH - FREE

TheStreet Quant Ratings rates Jarden Corporation as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, revenue growth, good cash flow from operations, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Jarden Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Illinois Tool Works (ITW) - FREE Research Report

Mccormack Robert C who is Director at Illinois Tool Works sold 104,000 shares at $80.11 on Dec. 11, 2013. Following this transaction, the Director owned 4.0 million shares meaning that the stake was reduced by 2.56% with the 104,000-share transaction.

The shares most recently traded at $78.45, down $1.66, or 2.12% since the insider transaction. Historical insider transactions for Illinois Tool Works go as follows:

  • 12-Week # shares bought: 7,000
  • 24-Week # shares bought: 7,000

The average volume for Illinois Tool Works has been 1.8 million shares per day over the past 30 days. Illinois Tool Works has a market cap of $35.4 billion and is part of the industrial goods sector and industrial industry. Shares are up 31.33% year-to-date as of the close of trading on Wednesday.

Illinois Tool Works Inc. manufactures and sells a range of industrial products and equipment worldwide. The stock currently has a dividend yield of 2.1%. The company has a P/E ratio of 15.3. Currently there are 8 analysts that rate Illinois Tool Works a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ITW - FREE

TheStreet Quant Ratings rates Illinois Tool Works as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins, good cash flow from operations and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Illinois Tool Works Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%